Avalon Pharma Stock (4016): Price, GoFinsa Rating and News
GoFinsa provides a guide to Avalon Pharma stock, listed under ticker 4016, including its economic sector and factors that can help investors assess the stock.
About Avalon Pharma and Its Business
Avalon Pharma (ticker 4016) operates in the Saudi market and manufactures or distributes pharmaceutical products. The company description identifies pharmaceutical products as part of its business. This overview describes the stated nature of its activities and products; it does not mean that every activity contributes equally to revenue or that any specific financial results have been achieved.
Avalon Pharma Stock Information
Avalon Pharma shares trade on the Saudi Exchange under ticker 4016. The company belongs to the pharmaceuticals sector. Following official disclosures and financial results can help investors understand the company’s position and the development of its business.
Avalon Pharma’s Business and Company Information
The company is classified in the pharmaceuticals sector in the Saudi market. Annual reports and official disclosures can be used to learn about its activities, revenue sources and operational development.
The Pharmaceuticals Sector in the Saudi Economy
The performance of listed companies in the pharmaceuticals sector is linked to demand for their products and services, operating costs, competition, and economic and regulatory conditions. Companies differ in how sensitive they are to these factors, depending on their business models.
How to Read the Stock’s Financial Results
It is important to compare revenue, profit, cash flows and debt across multiple financial periods, and to understand the reasons for changes rather than relying on the result for a single quarter. Official announcements should also be reviewed for material events.
Factors That May Affect the Stock Price
Avalon Pharma’s share price may be affected by company results and disclosures, trends in the Saudi market, interest rates and investor expectations. A change in the share price alone does not indicate an improvement in operating performance.
Investment Risks
Potential risks include share-price volatility, cost changes, weaker demand, competition and regulatory changes. The actual risks vary according to the company’s activities and financial position.
The Stock’s Investment Strength According to the GoFinsa Saudi Stocks Index
The recorded rating for the stock in the GoFinsa GFSI is 88%. This is an independent analytical rating, not a guarantee of profit or a personalized recommendation to buy.
Investing in Saudi Stocks
The Saudi market includes companies operating across a range of economic sectors. Before making an investment decision, investors can benefit from reviewing disclosures, comparing financial valuations, diversifying risk and setting an investment time horizon.
Following Company News
The latest disclosures and news relating to Avalon Pharma stock can be followed through the news sources and official data available on GoFinsa. Check the date of each item and how directly it relates to the company.
Avalon Pharma’s Reference Price
The recorded reference price is 63.25 SAR as of 2026-10-08. This is a historical price, not a live quote or a confirmed price for current trading.
Avalon Pharma’s Rating in the GoFinsa GFSI
The GoFinsa GFSI rating recorded for the stock is 88%. This is a GoFinsa research rating, not a recommendation to buy or sell.
Overview of the Pharmaceuticals Sector
Avalon Pharma stock belongs to the pharmaceuticals sector on the Saudi Exchange. Companies in the sector are affected by demand, competition, costs, and economic and regulatory conditions. Their risks and revenue sources vary from one company to another.
Trading Through XTB and the Risks
What Does Avalon Pharma Do?
Avalon Pharma (4016) belongs to the pharmaceuticals sector. The company’s candidate research scope includes the manufacture or marketing of medicines and health products. Precise details and any subsidiary activities should be checked against the company’s latest official profile before publication.
Where Does Avalon Pharma’s Revenue Come From?
When analyzing Avalon Pharma’s business model, review the following potential sources of income against the company’s published financial statements: sales of pharmaceutical products, distribution channels and exports, if any. Listing these items does not establish that each one makes an actual contribution to the company’s revenue.
Factors That Affect Avalon Pharma’s Stock Performance
Indicators relevant to Avalon Pharma’s business include drug registrations and pricing, production costs and competition. Trends should be compared across the company’s actual results for multiple periods. Growth or profitability should not be inferred without documented figures.
What to Check in the Annual Disclosure
When assessing Avalon Pharma (4016), first identify the date of the latest annual report. Then review the description of actual activities, operating segments and revenue recognition policy. Read the notes to the financial statements rather than relying only on management’s summary; the notes may disclose commitments or events that are not apparent from headline figures. Confirm the identity of the listed entity, its subsidiaries and the nature of their operations before attributing any activity or project to the company. A trend in the pharmaceuticals sector is not evidence of revenue growth at this company unless its published results support that conclusion.
How to Distinguish Genuine Growth from Accounting Changes
To analyze Avalon Pharma, compare results for multiple periods of similar duration and watch for non-recurring items, reclassifications and changes in the scope of consolidation. Higher revenue does not necessarily mean improved profitability if the cost of sales or expenses have risen faster. Examine operating and net profit margins, then review management’s notes for explanations of the changes. If reliable, up-to-date financial statements are not available, these remain analytical steps rather than a description of Avalon Pharma’s actual performance.
Cash Flows and the Ability to Finance Operations
When reviewing Avalon Pharma’s financial information, it is useful to distinguish accounting profit from cash generated by operations. Examine net operating cash flows, changes in working capital, capital expenditure and financing costs. A company may report profit while its cash declines because of increases in receivables or inventory, or project payments. Conversely, cash flows may be temporarily affected by the timing of collections and payments. The company’s liquidity or solvency cannot be assessed without the relevant financial statements and notes.
Debt and Financing Costs: Key Questions
If Avalon Pharma has financing obligations, start by identifying their maturity dates, the distribution of debt between short- and long-term obligations, borrowing costs and any contractual covenants. Assess how sensitive earnings and cash flows may be to changes in interest rates, taking into account whether financing instruments have fixed or variable rates. The relevance of these questions varies with the company’s business model in the pharmaceuticals sector. This guide does not assume that the company has any particular level of debt or risk.
Comparing the Stock with Sector Peers Without Misleading Conclusions
For a fair comparison of Avalon Pharma stock, select companies with similar activities, revenue mix, size and regulatory conditions. Compare revenue growth, margins, return on capital and cash flows, then account for differences in accounting and financial leverage. A lower price-to-earnings multiple than another company is not, by itself, enough to conclude that the stock is cheaper; the difference may reflect growth expectations, risk or earnings quality. Where a company reports losses or non-recurring profits, some valuation multiples may not be suitable for comparison.
How to Read the Reference Price and Its Date
The reference price shown in this guide is historical and dated; it is not a live bid or offer. When assessing Avalon Pharma, check which trading session the price refers to and whether capital changes, a share split or distributions may affect historical comparisons. Do not confuse the previous closing price with the latest trade or the average price during a session. If market data is not updated promptly, its date should be shown clearly, and an old figure should not be used to infer a new daily trend.
Building Scenarios Instead of Predicting a Specific Price
Three scenarios can be used to study Avalon Pharma: improving business conditions, conditions remaining unchanged, and a decline in demand or margins. For each scenario, identify measurable assumptions such as sales volume, input costs or financing expenses, then compare the results with published financial statements when available. Do not set a price target without a valuation model and documented inputs, and do not present the positive scenario as an expected outcome. The purpose of this approach is to understand how sensitive an investment may be to new information.
Checklist Before Making an Investment Decision
Before dealing in Avalon Pharma stock, confirm the ticker 4016, the company’s identity and the price date. Review the latest material disclosure, financial results and auditor’s notes, if any. Keep the GoFinsa research rating separate from the question of whether an investment suits your personal circumstances. Set your time horizon, assess your tolerance for loss and consider your portfolio’s exposure to the pharmaceuticals sector. Also review broker commissions and the type of financial instrument: directly owning shares differs from trading derivatives or contracts for difference, which may involve additional risks.
أسئلة شائعة عن الشركة
What is Avalon Pharma’s stock ticker?
Its ticker on the Saudi Exchange is 4016.
Which sector does Avalon Pharma stock belong to?
The stock belongs to the pharmaceuticals sector.
Is the GoFinsa rating a recommendation to buy?
No. The rating is an analytical tool and is not a personalized investment recommendation or a guarantee of future performance.